Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr; 1(1):80-7.
View in:
PubMed
subject areas
Adenine
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Clinical Trials as Topic
Disease Progression
DNA Mutational Analysis
Female
High-Throughput Nucleotide Sequencing
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Molecular Targeted Therapy
Mutation
Ohio
Phospholipase C gamma
Piperidines
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Pyrazoles
Pyrimidines
Recurrence
Risk Factors
Time Factors
Treatment Outcome
authors with profiles
Jeffrey A. Jones